In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

Silence pervades the site of Auschwitz-Birkenau today. Sometimes the only sounds are the soft footsteps of visitors, people who come from all over the world to mourn and to learn, and the voices of ...

Blending fantasy and romance is often overdone in the literary world today, but I was pleasantly surprised by the perfect ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $34.94 which represents a slight increase of $0.89 or 2.61% from the prior close of $34.05. The stock opened at $33.85 and ...

Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are ...